Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer
Vladislav Berdunov,Steve Millen,Andrew Paramore,Jane Griffin,Sarah Reynia,Nina Fryer,Rebecca Brown,Louise Longworth
DOI: https://doi.org/10.2147/CEOR.S360049
2022-09-20
ClinicoEconomics and Outcomes Research
Abstract:Vladislav Berdunov, 1 Steve Millen, 2 Andrew Paramore, 2 Jane Griffin, 3 Sarah Reynia, 2 Nina Fryer, 2 Rebecca Brown, 1 Louise Longworth 1 1 PHMR Ltd, London, UK; 2 Exact Sciences, London, UK; 3 Jane Griffin Associates, East Molesey, UK Correspondence: Vladislav Berdunov, PHMR Ltd, Berkeley Works, Berkley Grove, London, NW1 8XY, UK, Tel +44 20 3432 7450, Email Background: The 21-gene assay (the Oncotype DX Breast Recurrence Score ® test) is a validated multigene assay which produces the Recurrence Score ® result (RS) to inform decisions on the use of adjuvant chemotherapy in human epidermal growth factor receptor 2-negative (HER2-), hormone receptor positive (HR+) early invasive breast cancer. A model-based economic evaluation estimated the cost-effectiveness of the 21-gene assay against the use of clinical risk tools alone based on the latest evidence from prospective studies. Methods: The proportion of patients assigned to chemotherapy conditional on their RS result was obtained from retrospective data from the Clalit registry. The probability of distant recurrence with endocrine and chemo-endocrine therapy conditional on RS result was obtained from TAILORx and NSABP B-20 trials. The cost-effectiveness of the 21-gene assay compared to using clinical risk tools alone was estimated in terms of cost per quality-adjusted life-year (QALY) over a lifetime horizon. Results: The 21-gene assay was more effective (0.17 more quality-adjusted life years) at a lower cost (-£ 519) over a lifetime compared to clinical risk alone. The model results were sensitive to assumptions around the magnitude of benefit of chemotherapy in the high RS result subgroup. Other assumptions underpinning the model, such as the proportion of patients assigned to chemotherapy in the low and mid-range RS result subgroups and long-term distant recurrence probabilities, had a smaller impact on the results. Conclusion: The analysis showed that the cost-effectiveness of the 21-gene assay is sensitive to assumptions for chemotherapy sparing for patients with RS 0– 25 whose outcomes with endocrine therapy are no worse compared to chemotherapy-assigned patients, and a chemotherapy benefit in the RS 26– 100 group. Future studies need to incorporate a wider set of tumour profiling tests other than the 21-gene assay to allow a direct comparison of their cost-effectiveness. Keywords: cost-effectiveness, multigene assay, breast cancer, chemotherapy, the Oncotype DX test, 21-gene assay Breast cancer accounts for up to 25% of all malignancies in the world and represents the most common cause of cancer-related mortality in women. 1,2 Over 55,000 cases of breast cancer are diagnosed in the UK annually. 3 Breast cancer is often described by stage of development linked to invasive tumours of increasing severity. Early-stage invasive breast cancer refers to tumours that are either stage 1, 2 or 3A. The standard of care for early invasive breast cancer is breast-conserving surgery or mastectomy followed by adjuvant treatment for the prevention of metastases. 4,5 Over 70% of all breast cancer tumours are human epidermal growth factor receptor 2-negative (HER2-) and hormone receptor positive (HR+), 6 and this subset of patients, when treated appropriately, has the highest survival rate amongst the different molecular subtypes. 7 Targeted endocrine treatment significantly reduces the risk of distant recurrence of this type of breast cancer. 8 The addition of adjuvant chemotherapy can further reduce the risk of distant recurrence in a minority of HR+/HER2- patients. 9–12 However, the risk of chemotherapy-related toxicity needs to be weighed against the likelihood of long-term benefit of treatment. 13,14 Gene expression profiling of tumours using multigene assays (MGAs) can estimate the risk of distant recurrence and in some cases predict chemotherapy benefit, thus supporting decisions on the use of chemotherapy. The 21-gene assay (the Oncotype DX Breast Recurrence Score ® test, Exact Sciences, Madison, WI, USA) assesses the expression of 21 genes in tumor tissue and reports a Recurrence Score ® (RS ® ) result along with an estimate of the risk of distant recurrence and likely chemotherapy benefit. 15,16 The prognostic and predictive ability of the 21-gene assay has been explored in several large-scale prospective randomised studies, 17–20 and this level of evidence has led to its inclusion in clinical guidelines and adoption in clinical practice. 21 Recently, an alternative RS result cut-point of 25 has been applie -Abstract Truncated-